Citations

Mayo Clinic

Clear

1111 citation(s) found for "Vo, Pamela".

Factors Associated with Breast Cancer Prevention Communication between Mothers and Daughters
Frost, Marlene H., Vierkant, Robert A. , Petersen, Larra R., Rock, Emily, Clark, Lara P. , Vachon, Celine M. , Fredericksen, Zachary S., Sellers, Thomas A. , Cerhan, James R. , Sinicrope, Pamela S. , Brockman, Tabetha A. , Patten, Christi A. , Vachon, Celine M. , Cerhan, James R , Vierkant, Robert A

Journal of Women's Health | June 13, 2008 | Volume: 17 | Issue: 6 | Pages: 1017-1023

10.1089/jwh.2007.0497 | PMID 18554093 Get It

Objective: Mother-daughter communication may be a potential pathway between family history and cancer prevention behavior. We examined the degree to which mothers reported providing advice on breast cancer prevention to their daughters, the content of such advice, and correlates of providing such advice. Methods: Data were collected via a mailed questionnaire to 1773 women from 355 families in the Minnesota Breast Cancer Family Study. Women were asked whether or not they had provided advice to their daughters on what they should do to prevent breast cancer. An additional open-ended question asked them to describe the types of advice they had provided. Results: Nine hundred seventy-six (55%) of the women reported providing breast cancer prevention advice to their daughters. The most frequent types of advice were to have a mammogram (51%), perform breast self-examination (BSE) (39%), have a clinical breast examination (CBE) (30%), and maintain a healthy lifestyle (21%). From multivariate logistic regression, older age ( p < 0.001), having a personal history of breast cancer ( p < 0.001), higher degree of breast cancer worry/concern ( p < 0.001), engaging in a higher number of health-promoting behaviors ( p < 0.001), and ever performing a BSE ( p = 0.04) were factors independently associated with the provision of advice. Analyses accounting for sample nonindependence did not change our results. Conclusions: Breast cancer prevention behaviors were associated with providing advice. By better understanding the pathways through which breast cancer family history is associated with screening mammography and other prevention behaviors, researchers can develop more effective, tailored prevention interventions at the family level.
Development and Preliminary Validation of the Cancer Family Impact Scale for Colorectal Cancer
Vernon, Sally W. , Diamond, Pamela M., Kelder, Steven H. , Rabe, Kari G. , Petersen, Gloria M. , Sinicrope, Pamela S. , Patten, Christi A. , Chaffee, Kari G.

Genetic Testing | March 28, 2008 | Volume: 12 | Issue: 1 | Pages: 161-169

10.1089/gte.2007.0077 | PMID 18373413 Get It

Pathway analysis of primary central nervous system lymphoma
Personett, David, Baskerville, Karen A., Menke, David M. , Jaeckle, Kurt A. , Kreinest, Pamela, Edenfield, Brandy , Lai, Weil, Park, Peter J. , McKinney, Michael, Tun, Han W. , Zubair, Abba C. , O’Neill, Brian Patrick , Park, Peter J

Blood | January 10, 2008 | Volume: 111 | Issue: 6 | Pages: 3200-3210

10.1182/blood-2007-10-119099 | PMID 18184868 Get It

Abstract Primary central nervous system (CNS) lymphoma (PCNSL) is a diffuse large B-cell lymphoma (DLBCL) confined to the CNS. A genome-wide gene expression comparison between PCNSL and non-CNS DLBCL was performed, the latter consisting of both nodal and extranodal DLBCL (nDLBCL and enDLBCL), to identify a “CNS signature.” Pathway analysis with the program SigPathway revealed that PCNSL is characterized notably by significant differential expression of multiple extracellular matrix (ECM) and adhesion-related pathways. The most significantly up-regulated gene is the ECM-related osteopontin (SPP1). Expression at the protein level of ECM-related SPP1 and CHI3L1 in PCNSL cells was demonstrated by immunohistochemistry. The alterations in gene expression can be interpreted within several biologic contexts with implications for PCNSL, including CNS tropism (ECM and adhesion-related pathways, SPP1, DDR1), B-cell migration (CXCL13, SPP1), activated B-cell subtype (MUM1), lymphoproliferation (SPP1, TCL1A, CHI3L1), aggressive clinical behavior (SPP1, CHI3L1, MUM1), and aggressive metastatic cancer phenotype (SPP1, CHI3L1). The gene expression signature discovered in our study may represent a true “CNS signature” because we contrasted PCNSL with wide-spectrum non-CNS DLBCL on a genomic scale and performed an in-depth bioinformatic analysis.
Cholangiocyte cilia express TRPV4 and detect changes in luminal tonicity inducing bicarbonate secretion
Gradilone, Sergio A. , Masyuk, Anatoliy I. , Splinter, Patrick L., Bañales, Jesús M. , Huang, Bing , Tietz, Pamela S., Masyuk, Tatyana V. , LaRusso, Nicholas F. , Banales, Jesus M , Gradilone, Sergio A

Proceedings of the National Academy of Sciences | November 16, 2007 | Volume: 104 | Issue: 48 | Pages: 19138-19143

10.1073/pnas.0705964104 | PMID 18024594 Get It

Cholangiocytes, epithelial cells lining the biliary tree, have primary cilia extending from their apical membrane into the ductal lumen. Although important in disease, cilia also play a vital role in normal cellular functions. We reported that cholangiocyte cilia are sensory organelles responding to mechanical stimuli (i.e., luminal fluid flow) by alterations in intracellular Ca 2+ and cAMP. Because cholangiocyte cilia are also ideally positioned to detect changes in composition and tonicity of bile, we hypothesized that cilia also function as osmosensors. TRPV4, a Ca 2+ -permeable ion channel, has been implicated in signal transduction of osmotic stimuli. Using purified rat cholangiocytes and perfused intrahepatic bile duct units (IBDUs), we found that TRPV4 is expressed on cholangiocyte cilia, and that hypotonicity induces an increase in intracellular Ca 2+ in a TRPV4-, ciliary-, and extracellular calcium-dependent manner. The osmosensation of luminal tonicity by ciliary TRPV4 induces bicarbonate secretion, the main determinant of ductal bile formation, by a mechanism involving apical ATP release. Furthermore, the activation of TRPV4 in vivo , by its specific agonist, 4αPDD, induces an increase in bile flow as well as ATP release and bicarbonate secretion. Our results suggest that cholangiocyte primary cilia play an important role in ductal bile formation by acting as osmosensors.
Secreted Frizzled-Related Protein 1 Loss Contributes to Tumor Phenotype of Clear Cell Renal Cell Carcinoma
Zou, Hongzhi , Kreinest, Pamela, Childs, April C., Belmonte, Leandra S., LeGrand, Shauna N., Wu, Kevin J. , Luxon, Bruce A. , Sinha, Mala, Parker, Alexander S. , Sun, L-Z, Ahlquist, David A. , Wood, Christopher G. , Copland, John A. , Gumz, Michelle L.

Clinical Cancer Research | August 15, 2007 | Volume: 13 | Issue: 16 | Pages: 4740-4749

10.1158/1078-0432.ccr-07-0143 | PMID 17699851 Get It

Abstract Purpose: Incidence and mortality rates for renal cell carcinoma (RCC) have been rising for decades. Unfortunately, the molecular events that support RCC carcinogenesis remain poorly understood. In an effort to gain a better understanding of signaling events in clear cell RCC (cRCC), we investigated the antitumor activity of secreted frizzled-related protein 1 (sFRP1), a negative regulator of Wnt signaling. Experimental Design: Genomic profiling of cRCC tumors and patient-matched normal tissues was done and confirmed using quantitative PCR and immunohistochemistry. Methylation-specific PCR was done on patient samples to evaluate the mechanism responsible for sFRP1 loss. sFRP1 expression was restored in cRCC cells and the effects on tumor phenotype were characterized. Results: Genomic profiling, quantitative PCR, and immunohistochemistry indicated that loss of sFRP1 occurred in cRCC and papillary RCC patient tissues. Twelve Wnt-regulated genes were up-regulated in cRCC tissues, including c-myc and cyclin D1, potentiators of cell proliferation and survival. Methylation of the sFRP1 gene was one mechanism identified for attenuation of sFRP1 mRNA. Stable reexpression of sFRP1 in cRCC cells resulted in decreased expression of Wnt target genes, decreased growth in cell culture, inhibition of anchorage-independent growth, and decreased tumor growth in athymic nude mice. Conclusions: To our knowledge, this is the first report to show that stable restoration of sFRP1 expression in cRCC cells attenuates the cRCC tumor phenotype. Our data support a role for sFRP1 as a tumor suppressor in cRCC and that perhaps loss of sFRP1 is an early, aberrant molecular event in renal cell carcinogenesis.
EGFR-T790M Is a Rare Lung Cancer Susceptibility Allele with Enhanced Kinase Activity
Vikis, Haris G., Sato, Mitsuo , James, Michael A. , Wang, Daolong, Wang, Yian , Wang, Min , Jia, Dongmei , Liu, Yan , Bailey‐Wilson, Joan E. , Pinney, Susan M. , Petersen, Gloria M. , Wiest, Jonathan S., Fain, Pamela R., Schwartz, Ann G. , Gazdar, Adi F. , Gaba, Colette , Rothschild, Henry, Mandal, Diptasri , Kupert, Elena, Seminara, Daniela, Viswanathan, Avinash, Govindan, Ramaswamy , Anderson, Marshall W., You, Ming , Amos, Christopher I. , Andrade, Mariza de , Yang, Ping , Minna, John Dorrance , Wilson, Richard K , Pinney, Susan M , Govindan, Ramaswamy

Cancer Research | May 18, 2007 | Volume: 67 | Issue: 10 | Pages: 4665-4670

10.1158/0008-5472.can-07-0217 | PMID 17510392 Get It

Abstract The use of tyrosine kinase inhibitors (TKI) has yielded great success in treatment of lung adenocarcinomas. However, patients who develop resistance to TKI treatment often acquire a somatic resistance mutation (T790M) located in the catalytic cleft of the epidermal growth factor receptor (EGFR) enzyme. Recently, a report describing EGFR-T790M as a germ-line mutation suggested that this mutation may be associated with inherited susceptibility to lung cancer. Contrary to previous reports, our analysis indicates that the T790M mutation confers increased Y992 and Y1068 phosphorylation levels. In a human bronchial epithelial cell line, overexpression of EGFR-T790M displayed a growth advantage over wild-type (WT) EGFR. We also screened 237 lung cancer family probands, in addition to 45 bronchoalveolar tumors, and found that none of them contained the EGFR-T790M mutation. Our observations show that EGFR-T790M provides a proliferative advantage with respect to WT EGFR and suggest that the enhanced kinase activity of this mutant is the basis for rare cases of inherited susceptibility to lung cancer. [Cancer Res 2007;67(10):4665–70]
Telecare for Patients With Type 1 Diabetes and Inadequate Glycemic Control
Montori, Víctor M. , Helgemoe, Pamela K., Dean, Diana S., Leung, Teresa W., Smith, Steven A., Kudva, Yogish C. , Helgemoe, Pamela, Guyatt, Gordon , Montori, Victor M

Diabetes Care | March 5, 2007 | Volume: 27 | Issue: 5 | Pages: 1088-1094

10.2337/diacare.27.5.1088 | PMID 15111526 Get It

OBJECTIVE—To determine the efficacy of telecare (modem transmission of glucometer data and clinician feedback) to support intensive insulin therapy in patients with type 1 diabetes and inadequate glycemic control. RESEARCH DESIGN AND METHODS—Thirty-one patients with type 1 diabetes on intensive insulin therapy and with HbA1c &gt;7.8% were randomized to telecare (glucometer transmission with feedback) or control (glucometer transmission without feedback) for 6 months. The primary end point was 6-month HbA1c. To place our findings in context, we pooled HbA1c change from baseline reported in randomized trials of telecare identified in a systematic review of the literature. RESULTS—Compared with the control group, telecare patients had a significantly lower 6-month HbA1c (8.2 vs. 7.8%, P = 0.03, after accounting for HbA1c at baseline) and a nonsignificant fourfold greater chance of achieving 6-month HbA1c ≤7% (29 vs. 7%; risk difference 21.9%, 95% CI −4.7 to 50.5). Nurses spent 50 more min/patient giving feedback on the phone with telecare patients than with control patients. Meta-analysis of seven randomized trials of adult patients with type 1 diabetes found a 0.4% difference (95% CI 0–0.8) in HbA1c mean change from baseline between the telecare and control groups. CONCLUSIONS—Telecare is associated with small effects on glycemic control in patients with type 1 diabetes on intensive insulin therapy but with inadequate glycemic control.
Identification of a Novel Tumor Suppressor Gene p34 on Human Chromosome 6q25.1
Vikis, Haris G., Wang, Yian , Jia, Dongmei , Wang, Daolong, Bailey‐Wilson, Joan E. , Pinney, Susan M. , Petersen, Gloria M. , Wiest, Jonathan S., Fain, Pamela R., Schwartz, Ann G. , Gazdar, Adi F., Gaba, Colette , Rothschild, Henry, Mandal, Diptasri , Kupert, Elena, Seminara, Daniela, Liu, Yan , Viswanathan, Avinash, Govindan, Ramaswamy , Anderson, Marshall W., You, Ming , Wang, Min , Bierut, Laura Jean , Amos, Christopher I. , Andrade, Mariza de , Yang, Ping , Gazdar, Adi, Minna, John Dorrance , Wilson, Richard K , Pinney, Susan M , Govindan, Ramaswamy

Cancer Research | January 8, 2007 | Volume: 67 | Issue: 1 | Pages: 93-99

10.1158/0008-5472.can-06-2723 | PMID 17210687 Get It

Abstract In this study, we observed loss of heterozygosity (LOH) in human chromosomal fragment 6q25.1 in sporadic lung cancer patients. LOH was observed in 65% of the 26 lung tumors examined and was narrowed down to a 2.2-Mb region. Single-nucleotide polymorphism (SNP) analysis of genes located within this region identified a candidate gene, termed p34. This gene, also designated as ZC3H12D, C6orf95, FLJ46041, or dJ281H8.1, carries an A/G nonsynonymous SNP at codon 106, which alters the amino acid from lysine to arginine. Nearly 73% of heterozygous lung cancer tissues with LOH and the A/G SNP also exhibited loss of the A allele. In vitro clonogenic and in vivo nude mouse studies showed that overexpression of the A allele exerts tumor suppressor function compared with the G allele. p34 is located within a recently mapped human lung cancer susceptibility locus, and association of the p34 A/G SNP was tested among these families. No significant association between the less frequent G allele and lung cancer susceptibility was found. Our results suggest that p34 may be a novel tumor suppressor gene involved in sporadic lung cancer but it seems not to be the candidate familial lung cancer susceptibility gene linked to chromosomal region 6q23-25. [Cancer Res 2007;67(1):93–9]
Age or Factors Associated with Aging Attenuate Testosterone’s Concentration-Dependent Enhancement of the Regularity of Luteinizing Hormone Secretion in Healthy Men
Liu, Peter Y. , Takahashi, Paul Y. , Roebuck, Pamela D., Veldhuis, Johannes D. , Takahashi, Paul

The Journal of Clinical Endocrinology & Metabolism | July 26, 2006 | Volume: 91 | Issue: 10 | Pages: 4077-4084

10.1210/jc.2005-2811 | PMID 16868060 Get It

Abstract Background: Healthy older men have reduced testosterone (Te) production and frequent, small irregular LH pulses. Which is cause and which is effect are not known. Rationale: In model systems, frequent and irregular LH pulses reflect attenuated feedback inhibition by Te. Hypothesis: Factors associated with aging impair negative feedback by Te. Subjects and Setting: Healthy men at an academic medical center were studied. Methods: The study used quantification of the regularity of LH release patterns during blockade of gonadal steroidogenesis and graded transdermal Te addback in 18 healthy men aged 18–65 yr. Results: In the cohort as a whole, stepwise Te repletion repressed LH concentrations (P = 0.001) and enhanced the quantifiable orderliness of LH release patterns (P &lt; 0.001). By regression analysis, age attenuated the capability of increasing Te concentrations to regularize LH secretion patterns (P = 0.019). However, after a fixed GnRH stimulus, the effect of Te on LH regularity was invariant of the age factor (P = 0.16), thus pointing to a hypothalamic locus of impaired Te feedback. Summary: Aging disrupts the capability of systemic Te concentrations to maintain orderly LH secretion under endogenous, but not exogenous, GnRH drive. Conclusions: Age or factors associated with increased age reduce negative feedback by any given total Te concentration on hypothalamopituitary GnRH-LH outflow, thus contributing to disorderly LH secretion.
Quality of Life of Caregivers of Patients With Advanced-Stage Cancer
Clark, Matthew M. , Rummans, Teresa A. , Sloan, Jeff A. , Jensen, Andrus, Atherton, Pamela J. , Frost, Marlene H., Richardson, Jarrett W., Bostwick, John , Hanson, Jean, Brown, Paul D. , Johnson, Mary E.

American Journal of Hospice and Palliative Medicine® | June 15, 2006 | Volume: 23 | Issue: 3 | Pages: 185-191

10.1177/1049909106289074 | PMID 17060277 Get It

There has been much research documenting the impact of having a loved one diagnosed with advanced cancer, but little is known about how to reduce care-giver burden. In this randomized controlled trial, the authors examined the potential relationship of an advanced cancer patient’s participation in an 8-session, structured, multidisciplinary intervention on the care-giver’s burden and quality of life (QOL). Although the patients randomly assigned to the intervention (n = 54) demonstrated improved QOL compared to the control condition (n = 49) participants ( P < .05), there was no evidence that improving the patient’s QOL made an impact on the caregiver’s level of burden or the care-giver’s QOL. Further investigation is warranted in this area, including interventions specifically designed and targeted to both reduce caregiver burden and to improve caregiver QOL.